Viernes 14/07/20 Producción Indiatrial

[admin]

Friday

Eventos económicos


Ventas retail
Productividad
Producción industrial
Utilización de la capacidad instalada
Sentimiento del consumidor
Inventarios de negocios

Retail sales July 2.0% 7.5%
8:30 am Retail sales ex-autos July 1.1% 7.3%
8:30 am Productivity Q2 1.4% -0.9%
8:30 am Unit labor costs Q2 8.7% 5.1%
9:45 am Industrial production July 2.7% 5.4%
9:45 am Capacity utilization July 70.5% 68.6%
10 am Consumer sentiment index Aug. 71.7 72.5
10 am Business inventories

[admin]

LAST CHG %CHG
Crude Oil Futures 41.98 -0.26 -0.62
Brent Crude Futures 44.69 -0.27 -0.60
Gold Futures 1957.20 -13.20 -0.67
Silver Futures 26.745 -0.973 -3.51
DJIA Futures 27677 -146 -0.52
S&P 500 Futures 3355.50 -12.20 -0.36

[admin]

The U.S. has already invested billions on potential coronavirus vaccines. Here’s where the deals stand
PUBLISHED FRI, AUG 14 20206:30 AM EDT
Noah Higgins-Dunn
@HIGGINSDUNN
A small bottle labeled with a "Vaccine" sticker is held near a medical syringe.
A small bottle labeled with a “Vaccine” sticker is held near a medical syringe.
Dado Ruvic | Reuters
The U.S. has doled out billions to develop a vaccine against the coronavirus that has infected more than 5.1 million people across the country, locking in a minimum of 800 million doses as soon as the immunizations are cleared later this year or early next year.

So far, the deals with a handful of pharmaceutical giants have topped roughly $10.79 billion as part of Operation Warp Speed, a program led by several departments within the federal government to accelerate the development, manufacturing and distribution of vaccines and treatments to fight the coronavirus.


The operation aims to provide at least 300 million doses of a coronavirus vaccine by January 2021. In most of the agreements, HHS says the vaccines will be given to the American people for free if part of a vaccine campaign but healthcare professionals could charge for the cost of administering the vaccines.

“It is likely that at the beginning of next year we would have tens of millions of doses available,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, told reporters on a conference call alongside National Institutes of Health Director Dr. Francis Collins on July 27.

“I think as we get into 2021, several months in, that you would have vaccines that would be widely available,” Fauci said.

Experts say some the top vaccine candidates are already being manufactured “at risk,” meaning the doses are created and prepared for deployment before official approval from the U.S. Food and Drug Administration.

“We are investing in the development and manufacture of the top six vaccine candidates to ensure rapid delivery. The military is ready to go, they’re ready to deliver a vaccine to Americans as soon as one is fully approved by the FDA and we’re very close to that approval,” President Donald Trump said during a press conference at the White House Tuesday.


The U.S. is only obligated to pay the next traunch of funding if the vaccines are cleared by the Food and Drug Administration.

Here’s where the deals stand so far:

Moderna

Trump said on Aug. 11 that the U.S. government reached a deal with Massachusetts-based Moderna for 100 million doses of its leading vaccine candidate mRNA-1273.
The deal gives the federal government the option to purchase up to 400 million additional doses, according to a separate announcement from Moderna. The company said the deal is worth up to $1.53 billion.
The U.S. has already invested $955 million in Moderna’s vaccine development, bringing its total investment up to $2.48 billion, the company said.
Moderna’s vaccine candidate is in late-stage human trials. The company previously said it could expect results as early as October.
Johnson & Johnson

HHS announced on Aug. 5 that it reached a deal with Janssen, J&J’s pharmaceutical subsidiary, worth approximately $1 billion for 100 million doses of its vaccine.
The deal gives the federal government the option to order an additional 200 million doses, according to the announcement.
The U.S. earlier this year awarded J&J $456 million to develop its vaccine.
J&J’s experimental vaccine is currently in early-stage human trials and is expected to begin late-stage human trials in September, executives have previously said.
Sanofi and GlaxoSmithKline

Sanofi and GSK, which are co-developing a vaccine, announced on July 31 that HHS would pay up to $2.1 billion to develop and deliver 100 million doses of their potential candidate.
The U.S. will have the option to order an additional 500 million doses, the companies said.
More than half of the $2.1 billion investment will be used for further development of the vaccine while the remaining dollars will be used toward manufacturing the initial 100 million doses, the companies said.
Sanofi and GSK have previously predicted their vaccine will enter clinical trials in September and late-stage trials by the end of the year.
Pfizer and BioNTech

Germany-based BioNTech and Pfizer announced on July 22 that the U.S. agreed to buy 100 million doses of their potential coronavirus vaccine for up to $1.95 billion.
The agreement allows the U.S. to acquire an additional 500 million vaccine doses, the companies said.
The companies are jointly working on four vaccine candidates. The most advanced, called BNT162b1, began late-stage human trials in late July.
The companies said they aim to make up to 100 million doses by the end of 2020 and approximately 1.3 billion doses by the end of 2021.
Novavax

HHS announced on July 7 that it reached a deal with the Maryland-based drugmaker Novavax worth $1.6 billion to help the company with trials and manufacturing.
The federal government said Novavax will provide the U.S. with 100 million doses of its experimental coronavirus vaccine once approved as part of the deal.
Novavax’s vaccine, named NVX-CoV2373, generated a promising immune response in an early stage clinical trials and could begin late-stage trials as early as October.
The company said it hopes to begin delivering 100 million vaccine doses by the beginning of next year.
AstraZeneca

HHS announced on May 21 that it would pay AstraZeneca up to $1.2 billion for its experimental vaccine developed alongside researchers at the University of Oxford.
The U.S. will receive at least 300 million doses of the vaccine as part of its investment, HHS said.
In June, the U.K. based company said it’s working to deliver 2 billion doses of its vaccine, called AZD1222, and could begin delivering doses in the fall.
The company announced promising early-stage human trial results on July 20 and has begun late-stage human trials in the U.K., Brazil and South Africa.
— CNBC’s Berkeley Lovelace Jr. and Lucy Handley contributed to this report.

[admin]

Copper August 14,07:19
Bid/Ask 2.8765 - 2.8772
Change +0.0268 +0.94%
Low/High 2.8436 - 2.9058
Charts

Nickel August 14,07:18
Bid/Ask 6.4586 - 6.4631
Change +0.1293 +2.04%
Low/High 6.3270 - 6.4948
Charts

Aluminum August 14,07:18
Bid/Ask 0.7893 - 0.7895
Change +0.0050 +0.64%
Low/High 0.7831 - 0.7976
Charts

Zinc August 14,07:18
Bid/Ask 1.0712 - 1.0716
Change +0.0090 +0.85%
Low/High 1.0613 - 1.0760
Charts

Lead August 14,07:18
Bid/Ask 0.8762 - 0.8764
Change +0.0057 +0.66%
Low/High 0.8695 - 0.8776
Charts

Uranium Aug 10, 2020
Ux U308 price: 32.00
Change from
previ

[admin]

https://lta.reuters.com/articulo/china- ... A0O5-OUSLT

[admin]

https://lta.reuters.com/articulo/salud- ... 91Y9-OUSLT

[admin]

https://lta.reuters.com/articulo/salud- ... AKCN25A1EJ

[admin]

https://elcomercio.pe/lima/sucesos/coro ... c-noticia/

[admin]

https://www.expreso.com.pe/economia/bcr ... -millones/

[admin]

Stock market live updates: Dow futures down 100, airlines decline, Tesla rises on upgrades
CNBC.com staff
This is CNBC’s markets live blog that will be updated throughout the day.

3 MIN AGO
Stock futures under pressure as S&P 500 struggles to break above February high

U.S. stock futures were under pressure on Friday morning as the S&P 500 continues its struggles to break into record territory. Dow Jones Industrial Average futures dipped more than 100 points, or 0.4%. S&P 500 futures slipped 0.2% and Nasdaq 100 futures were up marginally. Airline stocks such as Delta and American fell in premarket trading along with cruise operators Carnival and Royal Caribbean. Entering Friday’s session, the S&P 500 was just 0.6% below an all-time high set on Feb. 19. The broader market index has traded above its record closing high several times this week, but has been unable to close above that mark. —Fred Imbert

[admin]

LAST CHG %CHG
DJIA 27773.36 -123.36 -0.44
S&P 500 3365.53 -7.90 -0.23
Nasdaq Composite 11040.10 -2.40 -0.02
Japan: Nikkei 225 23289.36 39.75 0.17
UK: FTSE 100 6070.14 -115.48 -1.87
Crude Oil Futures 42.10 -0.14 -0.33
Gold Futures 1962.80 -7.60 -0.39
Yen 106.56 -0.36 -0.34
Euro 1.1824

[admin]

https://lta.reuters.com/articulo/econom ... AKCN25A1P6

[admin]

https://lta.reuters.com/articulo/econom ... A1N4-OUSLT

[admin]

https://lta.reuters.com/articulo/mercad ... AKCN25A1RM

[admin]

CHG %CHG
DJIA 27895.05 -1.67 -0.01
S&P 500 3373.37 -0.06 -0.00
Nasdaq Composite 11003.66 -38.85 -0.35
Japan: Nikkei 225 23289.36 39.75 0.17
UK: FTSE 100 6092.02 -93.60 -1.51
Crude Oil Futures 42.13 -0.11 -0.26
Gold Futures 1955.30 -15.10 -0.77
Yen 106.47 -0.46 -0.43
Euro 1.1830